AgeX Therapeutics Secures Up to $20M Loan
Ticker: SER · Form: 8-K · Filed: Mar 7, 2024 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Agex Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Mar 7, 2024 |
| Risk Level | medium |
| Pages | 9 |
| Reading Time | 11 min |
| Key Dollar Amounts | $0.0001, $500,000, $13.20, $18.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt-financing, clinical-development, loan-agreement
TL;DR
AgeX just got a $20M loan from Oxford Finance to fund its drug development. First $5M drawn.
AI Summary
On March 5, 2024, AgeX Therapeutics, Inc. entered into a loan agreement with Oxford Finance LLC for up to $20 million. The initial draw was $5 million, with the remaining $15 million available in tranches based on AgeX achieving certain milestones. This financing is intended to support AgeX's ongoing clinical development programs.
Why It Matters
This new debt financing provides AgeX Therapeutics with crucial capital to advance its clinical trials, potentially accelerating the development and commercialization of its therapeutic candidates.
Risk Assessment
Risk Level: medium — The loan introduces financial leverage and repayment obligations, and future funding tranches are contingent on meeting specific development milestones.
Key Numbers
- $20.0M — Loan Facility (Total potential funding from Oxford Finance LLC.)
- $5.0M — Initial Draw (Amount drawn by AgeX Therapeutics on March 5, 2024.)
Key Players & Entities
- AgeX Therapeutics, Inc. (company) — Borrower
- Oxford Finance LLC (company) — Lender
- $20 million (dollar_amount) — Maximum loan amount
- $5 million (dollar_amount) — Initial loan draw
- March 5, 2024 (date) — Date of loan agreement
FAQ
What is the purpose of the loan from Oxford Finance LLC?
The loan is intended to support AgeX Therapeutics' ongoing clinical development programs.
What is the total amount AgeX Therapeutics can borrow under this agreement?
AgeX Therapeutics can borrow up to $20 million under the loan agreement.
When was the loan agreement entered into?
The loan agreement was entered into on March 5, 2024.
How much was initially drawn from the loan facility?
An initial amount of $5 million was drawn on March 5, 2024.
Are there any conditions for drawing the remaining loan amounts?
Yes, the remaining $15 million is available in tranches, subject to AgeX Therapeutics achieving certain milestones.
Filing Stats: 2,785 words · 11 min read · ~9 pages · Grade level 20 · Accepted 2024-03-07 16:47:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share AGE NYSE American Check
- $500,000 — , a Delaware corporation ("AgeX"), drew $500,000 of its credit available under the Amend
- $13.20 — ercisable at an exercise price equal to $13.20 per warrant (such exercise price reflec
- $18.00 — ercisable at an exercise price equal to $18.00 per warrant (such exercise price reflec
Filing Documents
- form8-k.htm (8-K) — 57KB
- 0001493152-24-009224.txt ( ) — 234KB
- age-20240305.xsd (EX-101.SCH) — 3KB
- age-20240305_lab.xml (EX-101.LAB) — 33KB
- age-20240305_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGEX THERAPEUTICS, INC. Date: March 7, 2024 By: /s/ Andrea E. Park Chief Financial Officer